Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency
Clinical trial NCT03580239 · UNKNOWN
Trial details
- NCT number
- NCT03580239
- Sponsor
- Tianjin Medical University Second Hospital
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-01
- Primary completion
- 2023-01-31
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.